Hospital-based interventional two-arm parallel comparative study on dydrogesterone vs combined oral contraceptive pills for functional ovarian cysts [version 1; peer review: awaiting peer review]

• Published in: F1000 research 2024, Vol.13, p.84
• Main Authors: Shaikh, Muneeba, Acharya, Neema
• Format: Article
• Language: English
• Subjects: Acne; Combined oral contraceptive pills; Cysts; Drug interaction; Dydrogesterone; Efficacy; eng; Fertility; Functional ovarian cysts; Gynecology; Hospitals; Intervention; Menstruation; Obstetrics; Oral contraceptives; Ovaries; Performance evaluation; Population studies; Regression analysis; Reproductive-age women; Safety; Statistical analysis; Study Protocol; Thromboembolism; Ultrasonic imaging
• ISSN: 2046-1402; 2046-1402
• DOI: 10.12688/f1000research.142012.1

Background Functional ovarian cysts are common among women of reproductive age, often necessitating medical intervention. This hospital-based interventional study compares the efficacy and safety of combined oral contraceptive pills (COC) and dydrogesterone in managing functional ovarian cysts. Methods This randomized controlled trial will be conducted over two years at the Department of Obstetrics & Gynecology, AVBRH, Datta Meghe Institute of Medical Sciences. The study population consists of reproductive-age women seeking care at the outpatient unit of Obstetrics and Gynecology at AVBRH hospital. The sample size of 46 participants per group has been calculated based on a 95% confidence interval and the estimated prevalence of functional ovarian cysts. Group A will receive low-dose COC for three menstrual cycles. At the same time, Group B will be administered dydrogesterone (10 mg twice daily) for ten days during the luteal phase, repeated across three cycles. Expected outcomes The primary outcomes include evaluating the recession of cysts within three months, monitoring alterations in menstrual patterns (frequency, regularity, duration, and volume), assessing the necessary treatment duration, and observing potential side effects (e.g., nausea, vomiting, weight gain, and acne) and complications (e.g., thromboembolism, delayed menstrual cycles post-treatment, and interactions with other drugs). Data analysis will encompass descriptive statistics, comparative tests, and regression models to assess the primary outcomes. The significance level for hypothesis testing will be 0.05 with a two-tailed approach. Registration CTRI/2023/04/051811.